Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.

Saved in:
Bibliographic Details
Title: Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
Authors: Kumar S; Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Spin P; EVERSANA, Burlington, ON, Canada., Bonar N; EVERSANA, Burlington, ON, Canada., Siddiqui M; EVERSANA, Burlington, ON, Canada., Shokoohi M; EVERSANA, Burlington, ON, Canada., Wang D; EVERSANA, Burlington, ON, Canada., Hou K; EVERSANA, Burlington, ON, Canada., West MED; EVERSANA, Burlington, ON, Canada., Hampp C; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Green J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Harnett J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Humblet O; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Breskin A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Ge W; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Jalbert JJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Sobel RE; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kroog GS; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Lorenc KR; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Ma Q; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Jagannath S; Mount Sinai Hospital, New York, NY, USA.
Source: Blood cancer journal [Blood Cancer J] 2026 Apr 01; Vol. 16 (1). Date of Electronic Publication: 2026 Apr 01.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41922313
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kumar+S%22">Kumar S</searchLink>; Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.<br /><searchLink fieldCode="AU" term="%22Weisel+KC%22">Weisel KC</searchLink>; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Spin+P%22">Spin P</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Bonar+N%22">Bonar N</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Siddiqui+M%22">Siddiqui M</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Shokoohi+M%22">Shokoohi M</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Wang+D%22">Wang D</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Hou+K%22">Hou K</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22West+MED%22">West MED</searchLink>; EVERSANA, Burlington, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Hampp+C%22">Hampp C</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Green+J%22">Green J</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Harnett+J%22">Harnett J</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Humblet+O%22">Humblet O</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Breskin+A%22">Breskin A</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ge+W%22">Ge W</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Jalbert+JJ%22">Jalbert JJ</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Sobel+RE%22">Sobel RE</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kroog+GS%22">Kroog GS</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lorenc+KR%22">Lorenc KR</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ma+Q%22">Ma Q</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Jagannath+S%22">Jagannath S</searchLink>; Mount Sinai Hospital, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2026 Apr 01; Vol. 16 (1). <i>Date of Electronic Publication: </i>2026 Apr 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41922313
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-026-01470-6
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kumar S
      – PersonEntity:
          Name:
            NameFull: Weisel KC
      – PersonEntity:
          Name:
            NameFull: Spin P
      – PersonEntity:
          Name:
            NameFull: Bonar N
      – PersonEntity:
          Name:
            NameFull: Siddiqui M
      – PersonEntity:
          Name:
            NameFull: Shokoohi M
      – PersonEntity:
          Name:
            NameFull: Wang D
      – PersonEntity:
          Name:
            NameFull: Hou K
      – PersonEntity:
          Name:
            NameFull: West MED
      – PersonEntity:
          Name:
            NameFull: Hampp C
      – PersonEntity:
          Name:
            NameFull: Green J
      – PersonEntity:
          Name:
            NameFull: Harnett J
      – PersonEntity:
          Name:
            NameFull: Humblet O
      – PersonEntity:
          Name:
            NameFull: Breskin A
      – PersonEntity:
          Name:
            NameFull: Ge W
      – PersonEntity:
          Name:
            NameFull: Jalbert JJ
      – PersonEntity:
          Name:
            NameFull: Sobel RE
      – PersonEntity:
          Name:
            NameFull: Kroog GS
      – PersonEntity:
          Name:
            NameFull: Lorenc KR
      – PersonEntity:
          Name:
            NameFull: Ma Q
      – PersonEntity:
          Name:
            NameFull: Jagannath S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1